AstraZeneca PLC: AZN (O): 2Q26: a solid print, all in all

研报英文原文证据摘录

AstraZeneca PLC: AZN (O): 2Q26: a solid print, all in all

t

is not necessarily a guide to, indicator of, or assurance of, future performance.

This report is directed to and intended only for our clients who are “eligible counterparties”, “professional clients”, “institutional

investors” and/or “professional investors” as defined by the aforementioned regulators, and must not be redistributed to retail

clients as defined by the aforementioned regulators. Retail clients who receive this report should note that the services of the

entities noted herein are not available to them and should not rely on the material herein to make an investment decision. The result

of such act will not hold the entities noted herein liable for any loss thus incurred as the entities noted herein are not registered/

authorised/ licensed to deal with retail clients and will not enter into any contractual agreement/arrangement with retail clients.

This report is provided subject to the terms and conditions of any agreement that the clients may have entered into with the entities

noted herein. All research reports are disseminated on a simultaneous basis to eligible clients through electronic publication to

our client portal.

The information in this report was prepared by Bernstein solely for the internal business use of our clients. Clients may store,

display, analyze, reformat and print the information in this report for this limited use only. Clients may not copy, alter, create

derivative works, resell, reverse engineer, commercially exploit, share or distribute any part of the information contained herein

for any purpose without Bernstein’s express written consent. These restrictions include extracting data or using the content to

develop indices or other products.